mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer

mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer

Small cell lung cancer (SCLC) is a recalcitrant malignancy with limited treatment options. Bromodomain and extraterminal domain inhibitors (BETis) have shown promising preclinical activity in SCLC, but the broad sensitivity spectrum limits their clinical prospects. Here, we performed unbiased high-t...

Full description

Bibliographic Details
Main Authors: Anju Kumari, Lisa Gesumaria, Yan-Jin Liu, V. Keith Hughitt, Xiaohu Zhang, Michele Ceribelli, Kelli M. Wilson, Carleen Klumpp-Thomas, Lu Chen, Crystal McKnight, Zina Itkin, Craig J. Thomas, Beverly A. Mock, David S. Schrump, Haobin Chen
Format: Article
Language:English
Published: American Society for Clinical investigation 2023-03-01
Series:JCI Insight
Subjects:
Oncology
Online Access:https://doi.org/10.1172/jci.insight.156657

Internet

https://doi.org/10.1172/jci.insight.156657

Similar Items